---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-385881"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2026-09-09T11:05:05+00:00"
generated_at: "2026-09-09T11:10:06.383991+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology raises $50M for diabetes-focused subsidiary Caspian; retains ~49% stake

## Summary
- Caspian Therapeutics, a new wholly owned subsidiary, raised $50.0M in Series A preferred stock on Sept 8, 2026.
- Kura invested $4.3M; post-financing Kura holds ~49.2% of Caspian's outstanding capital stock.
- Kura contributed rights to next-gen menin inhibitors for diabetes/cardiometabolic diseases, incl. KO-7246, to Caspian.
- Kura granted Caspian non-exclusive licenses to ziftomenib-related patents/data; received reciprocal license for R&D.
- Caspian solely responsible for development/regulatory/commercialization in diabetes field; Kura provides services under agreement.

## SEC filing metadata
- accession: 0001193125-26-385881
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2026-09-09T11:05:05+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312526385881/0001193125-26-385881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312526385881/d496500d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-385881
- JSON: https://secwatch.observer/filing/0001193125-26-385881.json
- Plain text: https://secwatch.observer/filing/0001193125-26-385881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.